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Abstract. – OBJECTIVE: Up to 50% of patients 
hospitalized for acute heart failure (AHF) show 
resistance to diuretics. This condition contrib-
utes to a prolonged hospital length of stay and a 
higher risk of death. This review aimed to inves-
tigate whether a diuretic therapeutic approach 
more effective than furosemide alone exists for 
patients with diuretic-resistant AHF.
MATERIALS AND METHODS: We identified 
all randomized controlled trials (RCTs) evaluat-
ing diuretic therapy in patients with diuretic-re-
sistant AHF. We searched Pubmed, BioMed Cen-
tral, and Cochrane CENTRAL databases.
RESULTS: Six RCTs were identified, involving 
a total of 845 patients. The P-score ranges from 
0.6663 for furosemide to 0.2294 for the tolvap-
tan-furosemide. We found no significant differ-
ences in efficacy for any drug comparison.
CONCLUSIONS: None of the diuretics con-
sidered in RCTs performed to date (tolvaptan, 
metolazone, hydrochlorothiazide, indapamide) 
appear to be more effective than furosemide 
therapy alone for the treatment of patients with 
diuretic-resistant AHF.
Key Words: 
Acute heart failure, Furosemide, Diuretic resistance, 
Tolvaptan, Efficacy, Network meta-analysis.
Abbreviations
AHF: Acute Heart Failure; RCT: Randomized Controlled 
Trial; RoB 2: Revised Cochrane risk-of-bias tool for 
randomized trials; SMD: Standardized Mean Difference; 
95% CI: 95% Confidence Interval.
Introduction
Acute heart failure accounts for >26 million 
hospitalizations per year worldwide1-3, and a 1-year 
mortality rate as high as 20-30%4, with an additive 
risk with each subsequent hospitalization5.  
Congestion is the most frequent clinical mani-
festation (70% of patients), with diuretics recom-
mended as first-line therapy6,7. Amongst those, 
loop diuretics are the most prescribed drugs, al-
though, despite the improvement in symptoms, at 
least 50% of patients fail to experience any weight 
loss due to reduced extracellular fluid retention, 
and up to 50% leave the hospital with residual 
congestion, leading to further readmissions and 
mortality8,9. 
Diuretic resistance has not an accepted 
unique definition, but it is commonly described 
as the failure to achieve effective decongestion 
despite an adequate dose of diuretic adminis-
tered10. Since diuretic resistance contributes 
to worsening heart failure and outcome, great 
effort is directed towards identifying the best 
therapeutic strategies11.
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The aim of this systematic literature review was to 
investigate whether a diuretic therapeutic approach 
exists that is more effective in treating patients with 
diuretic-resistant AHF than furosemide alone.
Materials and Methods 
Data Sources and Searches
We identified all randomized controlled trials 
(RCTs) evaluating patients’ medical therapy with 
diuretic-resistant AHF (i.e., the clinician-estab-
lished need to add a second diuretic to initial ther-
apy, usually a loop diuretic, to resolve a condition 
of acute congestive heart failure). We included 
studies performed in any hospital department. 
The following publication types were exclud-
ed: observational studies, conference abstracts, 
reviews, non-human studies, protocols, policy 
statements, and guidelines. 
The electronic search strategy applied stan-
dard filters for identifying related studies. The 
search was performed on the Medline (PubMed), 
BioMed Central, Scopus, Web of Science, and 
Cochrane CENTRAL databases, from inception 
to 31st January 2020, with language restrictions. 
Figure 1. PRISMA 2009 Flow-diagram for the search and selection process of articles. From: Moher D, Liberati A, Tetzlaff 
J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRIS-
MA Statement. PLoS Med 6(7): e1000097. doi: 10.1371/journal.pmed1000097. For more information, visit www.prisma-state-
ment.org.
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The meta-analysis was conducted according to 
the PRISMA guidelines12. Our search strategy’s 
specific details can be seen in the Online Data 
Supplement appended to this paper (Supplemen-
tary Material S1). The protocol for this system-
atic review was registered on PROSPERO (regis-
tration number CRD42020168905).
Data Extraction and Quality Assessment 
Two independent couples of reviewers (DO/
NF and FM/DP) identified all relevant titles and 
abstracts. Full-text copies of all potentially rel-
evant studies were then obtained for detailed 
evaluation by each pair of reviewers, and the 
data from each study were independently ex-
tracted using a standardized abstraction mod-
ule. One pair of reviewers (FM/DP) evaluated 
the data in the absence of author and journal 
names, institutional affiliations, and publica-
tion date. The data extracted from the docu-
ments were checked by an additional reviewer 
(LV) for accuracy. Each study was assessed for 
methodological quality using the revised Co-
chrane risk-of-bias tool for randomized trials 
(RoB 2). We examined each article for informa-
tion on the sampling method, the presence of a 
control group, the comparability of the control 
group (if included), and methods used to obtain 
the results.
Qualitative Analysis 
A narrative synthesis approach was used to 
explore each study’s characteristics and the vari-
ations between the studies. We collected demo-
graphic data, information about the study’s design 
and planning objectives, and information about 
the diuretic drugs and control groups compared. 
As an indication of therapeutic efficacy, the urine 
volume produced in the first 24 hours was consid-
ered. We did not consider a cut-off value of urine 
volume, but instead considered the comparison in 
terms of absolute quantities of urine produced in 
the post-treatment period. We adopted this out-
come because the subjective assessment of dys-
pnea improvement is prone to methodological 
bias, whereas measurement of the volume of urine 
produced is a pragmatic outcome. Unlike the uri-
nary sodium concentration, many of the studies 
involved reported the total amount of urine pro-
duced8. Furthermore, all biomarkers (creatinine, 
B-type natriuretic peptide, etc.) explored to date 
to verify the efficacy of diuretics have failed to 
demonstrate a linear correlation with achieving 
decongestion13.
Statistical Analysis 
A default fixed-effect model or random-ef-
fects model was used if a high degree of incon-
sistency/heterogeneity was detected through 
Cochran’s Q value. The I2 was used to measure 
the percentage of variation across studies due 
to heterogeneity rather than chance. When I2 
results between 50 and 90%, the heterogeneity 
is assumed as substantial, while I2 is 75-100%, 
the heterogeneity is considerable. Results were 
illustrated using forest plots. A funnel plot and 
Egger’s test for asymmetry were planned to 
evaluate potential publication bias. The stan-
dardized mean difference (SMD) and 95% con-
fidence interval (95% CI) were calculated ac-
cording to the intention-to-treat principle. Tau2 
defined the between-study variance. The differ-
ence in the estimates of the treatment effect be-
tween the treatment groups for each hypothesis 
was tested using a two-sided z test. A p-val-
ue <0.05 was considered statistically signifi-
cant. All statistical analyses were performed 
using the R environment (version. 3.6.1. The 
R Foundation for Statistical Computing; Vien-
na, Austria) with the ‘netmeta’ and ‘metacont’ 
packages14,15.
Results
Characteristics of the Included Studies
Diuretic resistance was considered as the per-
sistence of congestion (orthopnea, edema, pulmo-
nary rales, elevated jugular venous pulse, or con-
gestion on chest radiograph) despite the diuretic 
administration. Cox et al16 defined “diuretic-resis-
tance” as the production of less than 2 L of urine 
in 12 hours, despite a furosemide dosage greater 
than 240 mg/die. 
Six studies fulfilled the specified criteria in-
volving 845 patients16-21 (Figure 1). Four studies 
were double-blind RCTs, and 2 were open-label 
RCTs. All but 2 studies were multicenter studies.
Five out of the 6 studies investigated tolvap-
tan; 2 studied metolazone, 1 hydrochlorothiazide, 
and 1 indapamide. In 3 studies, one or more arms 
evaluated an incremental dose of furosemide. 
Only 2 of the 6 randomized trials considered a 
placebo-arm. All but 2 of the studies considered 
two intervention arms only; 1 considered three, 
and 1 investigated four intervention arms (Figure 
2). The observation time to define diuretic-resis-
tant varied from 6 to 48 hours (Table I).
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Diuretic Efficacy 
In all the studies considered, except for Udel-
son et al17, where the diuretic is not specified, the 
patients showed a diuretic resistance after treat-
ment with a loop diuretic or furosemide at equiv-
alent dosage. The amount of urine produced per 
24 hours ranges from 6,464 mL in the tolvaptan 
group compared to the furosemide group in the 
study by Matsue et al19, to 79 mL in the furose-
mide group compared to tolvaptan in the study 
by Inomata et al20 (Supplementary Material S2).
Analyzing the individual studies, the standard-
ized mean difference (SMD) in drug efficacy was 
not statistically significant for any of the direct 
comparisons: by evaluating the SMD values for 
each comparison, all confidence intervals cross the 
zero value (Supplementary Material S3). Evalu-
ating the P-score, the values range from 0.6663 for 
furosemide to 0.2294 for the tolvaptan-furosemide 
(Supplementary Material S4). The results for all 
the individual treatment comparisons (both direct 
and indirect), applying a fixed-effects model, are 
shown in Supplementary Material S5.
Finally, over-all Q value was 2.57 (degree of 
freedom = 3; p-value = 0.462), Q value within 
designs was 0.12 (d.f. = 1; p-value = 0.730) and 
between designs was 2.99 (d.f.= 2; p-value = 
0.224). I2 was 0% (95% CI 0.0%; 82.2%), so no 
random-effects model was required. The net heat 
plot shows no inconsistency about any direct evi-
dence in the whole network (Supplementary Ma-
terial S6). The summary forest plot substantially 
demonstrated no differences between treatment 
efficacy (Figure 3). 
Detection of Systematic Errors
Most of the trials included were at low risk of 
bias (Table II). Randomization seemed to be ade-
quate and correctly complied in all studies. How-
ever, regarding the two open-label studies, it was 
not possible to affirm the absence of bias (even 
unintentional bias) related to the experiment-
ers’ discretion. Only one study considered relief 
from dyspnea as the primary outcome of diuret-
ic therapy through a 7-point Likert scale18. This 
outcome could be subject to bias due to difficult 
Table I. Characteristics of the included studies and definition of “diuretic-resistance”. AHF: acute heart failure; HF: heart 
failure; n.s.: not specified.
Study Population Sample Definition Initial Treatment Dose Time  
  Size   considered
Udelson et al17 Patients admitted  83 Congestion signs n. s. n. s. 48 h
 with diagnosis   despite daily
 of HF (NYHA > II)  diuretic therapy 
Matsue et al19 AHF patients with  217 Congestion signs Furosemide n. s. 6 h
 renal dysfunction  despite daily 
   diuretic therapy 
Felker et al18 Patients with AHF 257 Congestion signs  Furosemide 40 mg 24 h
   despite daily oral 
   diuretic therapy 
Inomata et al20 HF patients with  81 Congestion signs Furosemide ≥ 40 mg n. s.
 fluid retention  despite daily  or equivalents
   diuretic therapy  
Cox et al16 Hospitalized patients  60 Total urine output Furosemide or > 240 mg 12 h
 with hypervolemic   of <2 l in the 12 h equivalents
 AHF  prior to enrollment  
Salahudin et al21 Patients admitted  150 Congestion signs Furosemide 40 mg x 3 12 h
 with diagnosis   despite intravenous
 of refractory HF   diuretic therapy
 (NYHA > III)
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objectivity. The Egger’s test, used to quantify the 
funnel plot’s asymmetry (Figure 4), was statisti-
cally significant, confirming asymmetry (p-value 
= 0.037). Specifically, some arms of the study by 
Udelson et al17 were affected by the small sample 
size.
Discussion
In our analysis, no differences were found 
between the different diuretic strategies for the 
treatment of diuretic-resistant AHF. Additionally, 
we did not detect any significant difference be-
tween any of the diuretics tested in the individual 
studies and patients receiving placebo. Therefore, 
there is no evidence that any therapeutic strategy 
among those studied in the literature is particular-
ly effective. Loop diuretics play a crucial role in 
Figure 2. A plot of the diuretics network. The thickness of the 
edges is proportional to the precision (the inverse of the vari-
ance) of each direct comparison. The blue trapeze represents 
the multi-arm trial. TLV-FUR: tolvaptan + furosemide.
Figure 3. Forest plot displaying the in-network comparisons 
with furosemide. TLV-FUR: tolvaptan + furosemide; SMD: 
standard mean difference; 95% CI: 95% confidence interval.
Table I. Characteristics of the included studies and definition of “diuretic-resistance”. AHF: acute heart failure; HF: heart 
failure; n.s.: not specified.
Study Population Sample Definition Initial Treatment Dose Time  
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 with diagnosis   despite daily
 of HF (NYHA > II)  diuretic therapy 
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been described in 20% to 50% of patients hospi-
talized for AHF26, and residual congestion at the 
time of discharge is recognized as negative prog-
nostic factor in terms of mortality and re-hospi-
talization11,13,27,28. The main underlying mecha-
nisms of diuretic resistance in AHF, resides in the 
renal tubule defect and consequent activation of 
the treatment of AHF. Although no evidence ex-
ists to define the first-choice diuretic and dosage, 
furosemide is the most used for patients admitted 
with AHF8,22,23. A reasonable response to diuret-
ics should result in approximately 3-4 L of urine 
per 40 mg of furosemide24 or an output greater 
than 1400 mL of urine25. Diuretic resistance has 
Figure 4. Comparison-adjusted funnel plot assessing the publication bias of the network studies. Small sample studies are 
placed in the bottom of the funnel; the large sample studies are in the up. Deviation from the center could represent a source 
of publication bias.































































































Udelson et al17 double-blind Multicentric 83 Tolvaptan Placebo 4 + + + + + +
Matsue et al19 open label Multicentric 217 Tolvaptan Furosemide 2 + ? + + ? ?
Felker et al18 double-blind Multicentric 257 Tolvaptan Placebo 2 + + + ? + ?
Inomata et al20 open label Multicentric 81 Tolvaptan Furosemide 2 + ? + + + ?
Cox et al16 double-blind Monocentric 60 Chlorothiazide Metolazone 3 + + + + + +
Salahudin et al21 double-blind Monocentric 150 Indapamide Metolazone 2 + + + + + +
Table II. Methodological quality assessment using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2).
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the vasoactive neuro-hormonal systems9,29-31. The 
prolonged or continuous use of loop diuretics may 
cause a diuretic “braking” through distal compen-
satory sodium reabsorption. This progressive loss 
of efficacy is probably linked to the characteristic 
“ceiling effect”, due to the progressive loss of so-
dium, which sometimes exceeds the correspond-
ing elimination of water and determines a form of 
diuretic resistance in heart failure patients32.
Various diuretic strategies have been explored 
in the literature to overcome diuretic-resistance. 
In individual comparison studies, these new di-
uretics showed clinical superiority over furose-
mide alone or placebo. Udelson et al17 demonstrat-
ed more consistent weight loss and urine produc-
tion in the tolvaptan group than placebo, but not 
compared with furosemide alone. However, the 
authors used a single 80 mg dose of furosemide 
– the same as used in all randomization arms; 
therefore, it is unknown whether further effects 
can be observed increasing the dosage of furose-
mide. Although the literature data are controver-
sial, high daily intravenous doses of furosemide 
(2.5 times the total daily oral dosage) effectively 
improve diuresis33. Matsue et al19 demonstrated 
the decongestion efficacy of tolvaptan, allowing a 
furosemide down-titration. However, it should be 
noted that this study was not blinded; thus, bias 
cannot be excluded, and no conclusion regarding 
tolvaptan superiority over furosemide could be 
drawn. 
Conversely, Felker et al18 detected significantly 
more weight and fluid loss in the group treated 
with tolvaptan and furosemide compared with 
the group treated with furosemide alone. Ino-
mata et al20 obtained the same results in patients 
with renal dysfunction. Cox et al16, comparing 
hydrochlorothiazide, metolazone and tolvaptan 
in AHF patients with diuretic-resistance, did not 
find greater efficacy in any of the three drugs 
compared to each other16. Likewise, Salahudin et 
al21 found no significant difference between in-
dapamide and metolazone. 
In our analysis, no single significant differenc-
es were found for both: the effect of one drug vs. 
another and between any of the diuretics tested in 
the individual studies and placebo. 
Therefore, there is no evidence that any thera-
peutic strategy among those studied in the litera-
ture is particularly effective. 
However, other drug strategies exist besides 
those compared, such as ethacrynic acid and ne-
siritide. Ethacrynic acid is a phenoxyacetic acid 
derivative belonging to the family of loop diuret-
ics that includes furosemide34. However, no com-
parative study exists in the literature addressing 
ethacrynic acid and furosemide, leaving the field 
open to the opinions and suggestions of the indi-
vidual clinicians. Nesiritide, on the other hand, is 
a recombinant formulation of type-B natriuretic 
peptide, and it acts through the counter-regula-
tion of the renin-angiotensin-aldosterone system. 
If the pathophysiological rationale underlying the 
clinical administration of nesiritide was robust, 
a randomized, double-blind, placebo-controlled 
trial – ASCEND-HF – failed to show any statisti-
cally significant difference in mortality or re-hos-
pitalization rates. However, nesiritide associated 
with furosemide has never been tested in a clini-
cal trial in patients with diuretic-resistance35. 
Given the abovementioned risks related to re-
sidual congestion in patients with heart failure, 
especially in terms of re-hospitalization, the de-
cline in cardiac and renal function, and, ultimate-
ly, mortality, some mechanical removal strategies 
of the intravascular volume have been tested. 
Ultrafiltration (or aquaferesis) has been imple-
mented in some trials to investigate whether the 
mechanical removal of intravascular volume (and, 
because of the absorption mechanism, interstitial 
fluid) presents a valid option36. However, all the 
studies conducted so far comparing ultrafiltration 
with diuretic therapy have failed to demonstrate 
any substantial advantages. So, whether ultrafil-
tration constitutes a particularly useful solution to 
diuretic-resistance remains to be determined37,38.
In conclusion, there is no one more effective 
therapeutic drug to decongest patients with AHF 
than furosemide. Furthermore, some therapeutic 
strategies require further study, either because 
they were not studied adequately or because they 
have not been explored at all (i.e., ethacrynic acid, 
other drug combinations, higher drug doses, and 
so on). 
Limitations 
Despite the absence of inconsistencies in the 
pooling data analysis, we cannot exclude some 
heterogeneity due to the individual studies’ dif-
ferent designs. For example, the dosage of the 
drugs used is variable (although it is around the 
standard dosages) for each study considered. Fur-
thermore, we considered the total volume of urine 
produced in 24 hours as the diuretic-resistance 
criterion, rather than a cut-off value. This for two 
reasons: first of all, because there is no shared uni-
vocal value in literature; and, secondly, because 
the absolute comparison between the different 
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diuretics considered can benefit from this choice, 
rather than a predetermined value that may not 
reflect the patient’s clinical needs. However, even 
this somewhat arbitrary choice could reduce the 
reliability of the result.
Conclusions
In short, there is no evidence supporting the ef-
ficacy of additional diuretic therapies than furose-
mide alone in treating acute heart failure patients 
with diuretic-resistance.
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